Poxel S.A. (PXXLF)
| Previous close | 5.82 |
| Open | 5.82 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 5.82 - 5.82 |
| 52-week range | 5.82 - 9.26 |
| Volume | |
| Avg. volume | 5 |
| Market cap | 146.124M |
| Beta (5Y monthly) | 1.56 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Poxel Announces Financial Calendar for 2022
LYON, France, January 04, 2022--POXEL SA (Euronext – POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced its calendar for the publication of financial information for 2022.
- Business Wire
Poxel Announces its Participation at Upcoming Investor and Scientific Conferences in January 2022
LYON, France, December 14, 2021--POXEL SA (Euronext – POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced its participation at upcoming investor and scientific conferences in January 2022.
- Business Wire
Poxel Announces the Formation of its Scientific Advisory Board for Rare Metabolic Diseases
LYON, France, December 06, 2021--POXEL SA (Euronext – POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced the formation of its Scientific Advisory Board (SAB) for rare metabolic diseases. The new SAB will initially focus on supporting Poxel's X-linked adrenoleukodystrophy (ALD) program.
